Publications
Diagnostic Criteria
Treatment Related
Diagnostic Criteria, Treatment Related
Filter by:
Clear all X
Showing All
Sorry, there are currently no results that match those criteria! Please try selecting fewer filters or clearing all search terms.
Year
Title
Publication
2025
A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model
2025
Ferritin, C-Reactive Protein and Soluble CD25 Distinguish TAFRO From HLH
2025
Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease
2025
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis
2025
The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes
2025
Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric Castleman disease patients
2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: Findings from the ACCELERATE registry
2025
No evidence for active viral infection in unicentric and idiopathic multicentric Castleman disease by Viral-Track analysis
2025
Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman Disease
2025
Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns
2024
Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis
2023
Immune-mediated thrombocytopenia and IL- 6-mediatedthrombocytosis observed in idiopathic multicentric Castleman disease
2023
Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy
2023
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes clinical trials & observations
2023
A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases
2023
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria
2023
Ongoing symptoms following complete surgical excision in unicentric Castleman disease
2023
Siltuximab administration results in spurious IL-6 elevation in peripheral blood
2023
Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
2022
How we manage idiopathic multicentric Castleman disease
2022
Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
2022
P1140: Time to tumor, symptomatic and laboratory responses following siltuximab treatment in idiopathic multicentric Castleman disease
2022
A prospective, multicenter study of bortezomib, cyclophosphamide and dexamethasone in relapsed/refractory iMCD
2022
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
2022
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling
2022
Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis
2022
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis
2022
Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine
2022
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary hemophagocytosis
2022
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
2022
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review
2022
P1733: Non-Hematological Malignancies in Idiopathic Multicentric Castleman Disease Patients: A Matched Cohort Analysis Using a Health Claims-Based Dataset
2022
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
2022
Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO
2022
The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
2021
TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy
2021
Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity
2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
2021
Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease
2021
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease
2021
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease
2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease
2020
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder
2020
Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease
2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
2019
Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review
2019
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease
2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease
2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data
2018
Effectiveness of Rituximab-Containing Treatment Regimens in Idiopathic Multicentric Castleman Disease
2018
Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology
2018
The full spectrum of Castleman disease: 273 patients studied over 20 years
2018
Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas
2018
A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease
2018
Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease
2018
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
2017
Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease
2017
Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses
2017
Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach
2017
TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease
2017
Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals ‘Chemokine Storm’ and Separates Clinical Subtypes
2017
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
2016
The collaborative network approach: a new framework for accelerating Castleman’s disease and other rare disease research
2016
Clinical Characterization of Castleman’s Disease in A Group of Pediatric Patients
2016
Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome
2016
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease
2015
Taking Control of Castleman disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research
2015
Multicentric Castleman’s Disease in a Child Revealed by Chronic Diarrhea
2015
Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor
2014
Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance
2014
Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial
2014
HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review
2014
Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease
2014
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy
2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease
2013
Eruptive Cherry Hemangiomatosis Associated With Multicentric Castleman Disease
2013
Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels
2012
Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease
2010
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy
2010
Successful treatment of Castleman’s disease with interleukin-1 receptor antagonist (Anakinra)
2007
Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease
2005
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease